In this podcast, Editor-in-Chief Anthony Rothschild discusses his editorial in the May-June 2022 issue about the use of antipsychotic medications for treatment of nonpsychotic patients. With four drugs approved by the FDA for use as augmentation for the treatment of nonpsychotic depression, and possibly a fifth soon, he advocates for more longitudinal studies to better understand the potential risks vs. benefits to this practice. While citing previous similar treatment approaches in the history of psychopharmacology, Dr. Rothschild advocates that until potentially serious adverse effects can be ruled out, the prescription of antipsychotic medications to nonpsychotic patients should be limited to those who are resistant to all other treatments.